Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma

Figure 1 In vivo kinetics of intravenous contrast ultrasound agents in the liver.

Figure 2 A 67-year-old man with a 1. 5-cm hepatocellular carcinoma nodule located in segment 3 of the liver. A: B-mode ultrasound (US) cannot clearly depict the hepatocellular carcinoma (HCC) nodule; B: Contrast-enhanced US shows enhancement of HCC focus (arrow) in early vascular phase after administration of sonazoid.

Figure 3 A 70-year-old man with a 2. 0-cm hepatocellular carcinoma nodule located in segment 6 of the liver. Contrast-enhanced ultrasound using sonazoid shows the defect (arrow) imaging in post-vascular phase. The defect lesion can be targeted for insertion of a single needle by extending the time limitation.